Tetraphase is a clinical-stage biopharmaceutical company that specializes in creating antibiotics for severe and life-threatening bacterial infections. Using its innovative chemistry technology, the company aims to combat multidrug-resistant (MDR) bacteria, which have been identified as crucial public health risks by the CDC. With a focus on addressing urgent medical needs, Tetraphase is pioneering new solutions to combat antibiotic resistance and improve patient outcomes.